Difference between revisions of "Hainsworth JD, et al. Target Oncol. (2016) cited as Ref 633 in DOI: 10.1038/s41392-020-0110-5 (Q9896)"

From Wikibase.slis.ua.edu
Jump to navigation Jump to search
(‎Created claim: DOI Identifier (P138): 10.1007/s11523-016-0434-9, #quickstatements; #temporary_batch_1590000649558)
(‎Created claim: Page(s) (P105): 643-653, #quickstatements; #temporary_batch_1590074839150)
 
(5 intermediate revisions by the same user not shown)
Property / PubMed ID
 +
Property / PubMed ID: 27154357 / rank
 +
Normal rank
Property / Publication Date
 +
2016
Timestamp+2016-01-01T00:00:00Z
Timezone+00:00
CalendarGregorian
Precision1 year
Before0
After0
Property / Publication Date: 2016 / rank
 +
Normal rank
Property / Published In Name String
 +
Target Oncol.
Property / Published In Name String: Target Oncol. / rank
 +
Normal rank
Property / Volume
 +
11
Property / Volume: 11 / rank
 +
Normal rank
Property / title
 +
A randomized open-label phase 2 study of the CXCR4 inhibitor LY2510924 in combination with sunitinib versus sunitinib alone in patients with metastatic renal cell carcinoma (RCC) (English)
Property / title: A randomized open-label phase 2 study of the CXCR4 inhibitor LY2510924 in combination with sunitinib versus sunitinib alone in patients with metastatic renal cell carcinoma (RCC) (English) / rank
 +
Normal rank
Property / Page(s)
 +
643-653
Property / Page(s): 643-653 / rank
 +
Normal rank

Latest revision as of 15:47, 21 May 2020

Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
Language Label Description Also known as
English
Hainsworth JD, et al. Target Oncol. (2016) cited as Ref 633 in DOI: 10.1038/s41392-020-0110-5
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8

    Statements

    Hainsworth JD
    0 references
    0 references
    2016
    0 references
    Target Oncol.
    0 references
    11
    0 references
    A randomized open-label phase 2 study of the CXCR4 inhibitor LY2510924 in combination with sunitinib versus sunitinib alone in patients with metastatic renal cell carcinoma (RCC) (English)
    0 references
    643-653
    0 references